MNDAustralia say on their website that this is the second part...

MNDAustralia say on their website that this is the second part of the first phase SPG302 trial will be in Adelaide, Sydney and Brisbane and it will be a short four week trial followed by an open label trial. https://www.mndaustralia.org.au/articles/spg302-trial-set-to-begin-in-melbourne I find this interesting as it implies the first part, which iirc was to be held in Melbourne, is already complete, which I had heard nothing about. Spinogenix's drug takes a very different tack from ours - the aim of using their SPG302 molecule is to encourage new growth of new synapses between nerve cells, no doubt to replace those damaged and lost by MND/ALS, a contrast to our monepantel, which aims at cleaning up the damaging, misfolded proteins through upregulating autopagy via the mTOR system, and that way slowing (or stopping) the damage caused by the disease that cause the nerve cell synapse damage and destruction. The way I see it is that these two treatments are not really in competition, but targeting different aspects of MND and down the track may end up actually being complementary. But to my inexpert opinion,, the first priority should be on stopping the progress of MND, and that's exactly what monepantel is about. But, this is just my uneductaed opinion. @kpax, what do you think?